This is an old revision of the document!
Reliance Life Sciences
History
COVID-19
Reliance is developing a “second-generation” two antigen subunit protein COVID-19 vaccine called RelCoVax.1) On September 21, 2021, Dr. Robert Malone pitched RelCoVax to an online audience at the Vaccines Summit-2021.2)
1)
Phatarphekar, A., Vidyadhar Reddy, G. E. C., Gokhale, A., Karanam, G., Kuchroo, P., Shinde, K., Masand, G., Pagare, S., Khadpe, N., Pai, S. S., Vijayan, V., Ramnath, R. L., Pratap Reddy, K., Rao, P., Harinarayana Rao, S., & Ramana, V. (2022). RelCoVax®, a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice. Vaccine, 40(32), 4522–4530. https://doi.org/10.1016/j.vaccine.2022.06.026